![Minakem Generic APIs](https://www.pharmacompass.com/image/flap/minakem-header-desktop-w27gif-57924.gif)
![Minakem Generic APIs](https://www.pharmacompass.com/image/flap/minakem-header-mobile-w27gif-62411.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.prnewswire.com/news-releases/number-of-shares-and-votes-in-medivir-ab-on-28-june-2024-302185603.html
https://www.prnewswire.com/news-releases/fostrox--lenvima-holds-promise-of-greatly-improved-outcomes-for-advanced-liver-cancer-patients-reveals-new-data-from-medivir-at-esmo-gi-302184220.html
https://www.prnewswire.com/news-releases/medivir-selects-global-cro-partner-for-upcoming-phase-2b-study-in-hcc-with-fostrox--lenvima-and-initiates-study-feasibility-302176636.html
https://www.prnewswire.com/news-releases/issue-repurchase-and-reclassification-of-shares-of-series-c-and-transfer-of-ordinary-shares-under-ltip-2024-302159301.html
https://www.prnewswire.com/news-releases/medivir-to-present-at-redeye-growth-day-302159105.html
https://www.prnewswire.com/news-releases/medivirs-licensee-tango-therapeutics-has-discontinued-development-of-its-tng348-clinical-program-302154264.html
https://www.prnewswire.com/news-releases/resolutions-at-the-annual-general-meeting-in-medivir-on-7-may-2024-302138285.html
https://www.prnewswire.com/news-releases/medivir-ab--interim-report-january--march-2024-302131228.html
https://www.prnewswire.com/news-releases/medivir-to-present-data-for-the-combination-of-fostrox--lenvima-in-hcc-at-esmo-gi-302129837.html